Regulatory approval
Published by the Health Canada. Approved
NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | ER positive, HER2-positive, PR positive | Invasive Breast Carcinoma | Neratinib | |
| HC (1) | ER positive, HER2-positive | Invasive Breast Carcinoma | Neratinib | |
| HC (1) | HER2-positive, PR positive | Invasive Breast Carcinoma | Neratinib |